Increasingly high cell density, high product titer cell cultures containing mammalian cells are being used for the production of recombinant proteins. These high productivity cultures are placing a larger burden on traditional downstream clarification and purification operations due to higher product and impurity levels. Controlled flocculation and precipitation of mammalian cell culture suspensions by acidification or using polymeric flocculants have been employed to enhance clarification throughput and downstream filtration operations.
View Article and Find Full Text PDFThe processing of recombinant proteins from high cell density, high product titer cell cultures containing mammalian cells is commonly performed using tangential flow microfiltration (MF). However, the increased cellular debris present in these complex feed streams can prematurely foul the membrane, adversely impacting MF capacity and throughput. In addition, high cell density cell culture streams introduce elevated levels of process-related impurities, which increase the burden on subsequent purification operations to remove these complex media components and impurities.
View Article and Find Full Text PDFThe dramatic advances in recombinant DNA and proteomics technology over the past decade have supported a tremendous growth in biologics applied to diagnostics, biomarkers, and commercial therapeutic markets. In particular, antibodies and fusion proteins have now become a main focus for a broad number of clinical indications, including neurology, oncology, and infectious diseases with projected increase in novel first-class molecules and biosimilar entities over the next several years. In line with these advances are the improved analytical, development, and small-scale preparative methods employed to elucidate biologic structure, function, and interaction.
View Article and Find Full Text PDF